MRNS News and Press, Marinus Pharmaceuticals Inc. From 06/06/24

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired Marinus P...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - June 6, 2024) - Faruqi & Faruqi, LLP, a leading national sec...

2024-05-17 08:39:32 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus stock falls 9% amid Q1 report, cost-cutting measures Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints ...

Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 USPTO grants additional method of use patent for ganaxolone in TSC Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of ...

2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...

2024-05-08 16:15:29 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints Marinus Pharmaceuticals Q4 2023 Earnings Preview Seeking Al...

2024-05-08 07:22:41 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints Marinus Pharmaceuticals Q4 2023 Earnings Preview Seeking Al...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

ZTALMY ® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35 million Enrollment to be completed mid-May in the Phase 3 TrustTSC trial ...

2024-05-07 14:08:21 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints Marinus Pharmaceuticals Q4 2023 Earnings Preview Seeking Al...